Increased multidrug resistance-associated protein activity in mononuclear cells of patients with systemic lupus erythematosus

Clinical and Experimental Rheumatology

Volumn 26, Issue 4, 2008, Pages 638-645

  Lu, Ming Chi ^a   Lai, Ning Sheng ^a   Li, Ko Jen ^a   Hsieh, Song Chou ^b   Wu, Cheng Han ^b   Yu, Chia Li ^b  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Mononuclear cells; Multidrug resistance; Multidrug resistance associated proteins; P glycoprotein; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; BREAST CANCER RESISTANCE PROTEIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DICHLORODIHYDROFLUORESCEIN DIACETATE; GLYCOPROTEIN P; HYDROXYCHLOROQUINE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; PREDNISOLONE; RHODAMINE 123;

ADULT; ARTICLE; CELL ISOLATION; CELL TRANSPORT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG RESPONSE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LONG TERM CARE; MALE; MONONUCLEAR CELL; MULTIDRUG RESISTANCE; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; THERAPY RESISTANCE; TREATMENT DURATION; VOLUNTEER;

ADRENAL CORTEX HORMONES; ADULT; CASE-CONTROL STUDIES; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MITOXANTRONE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEUTROPHILS; RHODAMINES; YOUNG ADULT;

EID: 52749086076     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. GREENSTEIN B: Steroid resistance: implications for lupus. Lupus 1994; 3: 143-9.
2. PÉREZ-TOMÁS R: Multidrug resistance: retrospect and prospect in anti-cancer drug treatment. Curr Med Chem 2006; 13: 1859-76.
3. SZAKÁCS G, PATERSON JK, LUDWIG JA, BOOTH-GENTHE C, GOTTESMAN MM: Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5: 219-34.
4. LAGE H: ABC-transporters: implications on drug resistance from microorganisms to human cancers. Int J Antimicrob Agents 2003; 22: 188-99.
5. MORSCHHÄUSER J: The genetic basis of fluconazole resistance development in Candida albicans. Biochim Biophys Acta 2002; 1587: 240-8.
6. BORST P, ELFERINK RO: Mammalian ABC transporters in health and disease. Ann Rev Biochem 2002; 71: 537-92.
7. JANSEN G, SCHEPER RJ, DIJKMANS BA: Multidrug resistance proteins in rheumatoid arthritis, role in disease-modifying antirheumatic drug efficacy and inflammatory processes: an overview. Scand J Rheumatol 2003; 32: 325-36.
8. JORGENSEN C, SUN R, ROSSI JF et al.: Expression of a multidrug resistance gene in human rheumatoid synovium. Rheumatol Int 1995; 15: 83-6.
9. LLORENTE L, RICHAUD-PATIN Y, DÍAZ-BORJÓN A et al.: Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part I: Increased P-glycoprotein activity in lymphocytes from rheumatoid arthritis patients might influence disease outcome. Joint Bone Spine 2000; 67: 30-9.
10. VAN DER HEIJDEN JW, DUKMANS BA, SCHEPER RJ, JANSEN G: Drug Insight: resistance to methotrexate and other disease-modifying antirheumatic drugs--from bench to bedside. Nat Clin Pract Rheumatol 2007; 3: 26-34.
11. MAILLEFERT JF, MAYNADIE M, TEBIB JG et al.: Expression of the multidrug resistance glycoprotein 170 in the peripheral blood lymphocytes of rheumatoid arthritis patients. The percentage of lymphocytes expressing glycoprotein 170 is increased in patients treated with prednisolone. Br J Rheumatol 1996; 35: 430-5.
12. YUDOH K, MATSUNO H, NAKAZAWA F, YONEZAWA T, KIMURA T: Increased expression of multidrug resistance of P-glycoprotein on Th1 cells correlates with drug resistance in rheumatoid arthritis. Arthritis Rheum 1999; 42: 2014-5.
13. DÍAZ-BORJÓN A, RICHAUD-PATIN Y, ALVARADO DE LA BARRERA C, JAKEZ-OCAMPO J, RUIZ-ARGÜELLES A, LLORENTE L: Multi-drug resistance-1 (MDR-1) in rheumatic autommume disorders. Part II: Increased P-glycoprotein activity in lymphocytes from systemic lupus erythematosus patients might affect steroid requirements for disease control. Joint Bone Spine 2000; 67: 40-8.
14. TSUJIMURA S, SAITO K, NAKAYAMADA S, NAKANO K, TANAKA Y: Clinical relevance of the expression of P-glycoprotein on peripheral blood lymphocytes to steroid resistance in patients with systemic lupus erythematosus. Arthritis Rheum 2005; 52: 1676-83.
15. LAUPÈZE B, AMIOT L, COURTOIS A et al.: Use of the anionic dye carboxy-2′,7′-dichlorofluorescein for sensitive flow cytometric detection of multidrug resistance-associated protein activity. Int J Oncol 1999; 15: 571-6.
16. DRÉNOU B, FARDEL O, AMIOT L, FAUCHET R: Detection of P glycoprotein activity on normal and leukemic CD34+ cells. Leuk Res 1993; 17: 1031-5.
17. MALIEPAARD M, VAN GASTELEN MA, DE JONG LA et al.: Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 1999; 59: 4559-63.
18. LEITH CP, KOPECKY KJ, CHEN IM et al.: Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/ P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 1999; 94: 1086-99.
19. YOUNG IT: Proof without prejudice: use of the Kolmogorov-Smimov test for the analysis of histograms from flow systems and other sources. J Histochem Cytochem 1977; 25: 935-41.
20. BECK WT, GROGAN TM, WILLMAN CL et al.: Methods to detect P-glycoprotein- associated multidrug resistance inpatients' tumors: consensus recommendations. Cancer Res 1996; 56: 3010-20.
21. TAZZARI PL, CAPPELLINI A, RICCI F et al.: Multidrug resistance-associated protein I expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia 2007; 21: 427-38.
22. WU T, QIN X, KUREPA Z et al.: Shared signaling networks active in B cells isolated from genetically distinct mouse models of lupus. J Clin Invest 2007; 117: 2186-96.
23. OERLEMANS R, VAN DER HEUDEN J, VINK J et al.: Acquired resistance to chloroquine in human CEM T cells is mediated by multidrug resistance- associated protein I and provokes high levels of cross-resistance to glucocorticoids. Arthritis Rheum 2006; 54: 557-68.
24. VAN DER HEUDEN J, DE JONG MC, DIJKMANS BA et al.: Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFalpha. Ann Rheum Dis 2004; 63: 138-43.
25. VAN DER HEIJDEN J, DE JONG MC, DIJKMANS BA et al.: Acquired resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to non-related DMARDs. Ann Rheum Dis 2004; 63: 131-7.
26. RICHAUD-PATIN Y, VEGA-BOADA F, VIDALLER A, LLORENTE L: Multidrug resistance-1 (MDR-1) in autoimmune disorders IV. P-glycoprotein overfunction in lymphocytes from myasthenia gravis patients. Biomed Pharmacother 2004; 58: 320-4.
27. RUIZ-SOTO R, RICHAUD-PATIN Y, LÓPEZ-KARPOVITCH X, LLORENTE L: Multidrug resistance-1 (MDR-1) in autoimmune disorders III: increased P-glycoprotein activity in lymphocytes from immune thrombocyto- penic purpura patients. Exp Hematol 2003; 31: 483-7.
28. FOXWELL BM, MACKIE A, LING V, RYFFEL B: Identification of the multidrug resistance- related P-glycoprotein as a cyclosporine binding protein. Mol Pharmacol 1989; 36: 543-6.
29. ROBERT J, JARRY C: Multidrug resistance reversal agents. J Med Chem 2003; 46: 4805-17.
30. TAN B, PIWNICA-WORMS D, RATNER L: Multidrug resistance transporters and modulation. Curr Opin Oncol 2000; 12: 450-8.
31. AOUALI N, EDDABRA L, MACADRt J, MOR- JANI H: Immunosuppressors and reversion of multidrug-resistance. Crit Rev Oncol Hemalot 2005; 56: 61-70.
32. OKEKE IN, KLUGMAN KP, BHUTTA ZA et al.: Antimicrobial resistance in developing countries. Part II: strategies for containment. Lancet Infect Dis 2005; 5: 568-80.
33. FRANK MH, DENTON MD, ALEXANDER ST, KHOURY SJ, SAYEGH MH, BRISCOE DM: Specific MDR1 P-glyeoprotein blockade inhibits human alloimmune T cell activation in vitro. J Immunol 2001; 166: 2451-9.
34. DRACH J, GSUR A, HAMILTON G et al.: Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes. Blood 1996; 88: 1747-54.
35. GOLLAPUDI S, KIM C, GUPTA S: P-glycoprotein (encoded by multidrug resistance genes) is not required for interleukin-2 secretion in mice and humans. Genes Immun 2000; 1: 317-9.
36. ROBBIANI DF, FINCH RA, JÄGER D, MULLER WA, SARTORELLI AC, RANDOLPH GJ: The leukotriene C(4) transporter MRP1 regulates CCL19 (MIP-3beta, ELC)-dependent mobilization of dendritic cells to lymph nodes. Cell 2000; 103: 757-68.
37. TSUJIMURA S, SAITO K, NAKAYAMADA S et al.: Transcriptional regulation of multidrug resistance-1 gene by interleukin-2 in lymphocytes. Genes Cells 2004; 9: 1265-73.
38. HARTMANN G, CHEUNG AK, PIQUETTE-MILLER M: Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia. J Pharmacol Exp Ther 2002; 303: 273-81.
39. LEE G, PIQUETTE-MILLER M: Cytokines alter the expression and activity of the multidrug resistance transporters in human hepatoma cell lines; analysis using RT-PCR and cDNA microarrays. J Pharm Sci 2003; 92: 2152-63.
40. DREUW A, HERMANNS HM, HEISE R et al.: Interleukin-6-type cytokines upregulate expression of multidrug resistance-associated proteins in NHEK and dermal fibroblasts. J Invest Dermatol 2005; 124: 28-37.